Impact of rituximab on stem cell mobilization following ACVBP regimen in poor‐risk patients with diffuse large B‐cell lymphoma: results from a large cohort of patients

BACKGROUND: The ACVBP regimen is an efficient induction regimen for poor‐risk patients with diffuse large B‐cell lymphoma (DLBCL) before consolidative autologous stem cell transplantation. Adjunction of the monoclonal anti‐CD20 antibody rituximab (R‐ACVBP) was recently found to be superior to ACVBP alone. This study assessed the impact of rituximab on stem cell mobilization in two similar consecutive groups of patients treated with ACVBP in two prospective, controlled trials.

[1]  T. Molina,et al.  Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.

[2]  G. Salles,et al.  Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA , 2011, Haematologica.

[3]  B. Coiffier,et al.  Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[5]  Sung Sook Lee,et al.  Rituximab‐ESHAP as a mobilization regimen for relapsed or refractory B‐cell lymphomas: a comparison with ESHAP , 2007, Transfusion.

[6]  T. Miyamoto,et al.  Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma , 2007, Bone Marrow Transplantation.

[7]  D. Spierings,et al.  Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis1 , 2007, The Journal of Immunology.

[8]  X. Mariette,et al.  Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. , 2007, Haematologica.

[9]  J. Bourhis,et al.  Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: A large multicenter comparative study in patients with malignant lymphoma , 2007, Leukemia & lymphoma.

[10]  R. Bouabdallah,et al.  A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma , 2006, Bone Marrow Transplantation.

[11]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[13]  M. Bernard,et al.  Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. , 2006, Haematologica.

[14]  B. Bonavida,et al.  Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis , 2005, Oncogene.

[15]  W. Wilson,et al.  B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. , 2005, Blood.

[16]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Franke,et al.  The role of diagnosis in patients failing peripheral blood progenitor cell mobilization , 2004, Transfusion.

[18]  G. Salles,et al.  Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma , 2004, Bone Marrow Transplantation.

[19]  T. Koike,et al.  Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma , 2004, Bone Marrow Transplantation.

[20]  R. Gressin,et al.  Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. , 2004, The New England journal of medicine.

[21]  M. Cavazzana‐Calvo,et al.  Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure. , 2004, Haematologica.

[22]  T. Molina,et al.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.

[23]  M. Czuczman,et al.  Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients , 2003, Bone Marrow Transplantation.

[24]  S. Seeber,et al.  Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  J. Canon,et al.  Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies , 2003, Transfusion.

[26]  R. Porcher,et al.  High‐dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose , 2002, Transfusion.

[27]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[28]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[29]  G. Salles,et al.  Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. , 2001, The hematology journal : the official journal of the European Haematology Association.

[30]  P. Gaulard,et al.  Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Deakin,et al.  Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[33]  N. Schmitz,et al.  Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. , 1995, Blood.

[34]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Goldschmidt,et al.  Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. , 1994, Blood.